ArticleBrain and behavior2026
Statin Therapy Protects White Matter in Cerebral Small Vessel Disease Independent of Lipid-Lowering: Biomarker and Neuroimaging Evidence.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCerebral small vessel disease (CSVD) is characterized by white matter damage, but the roles of hyperlipidemia and statin therapy in its pathogenesis remain controversial. This study aimed to investigate the independent effects of statin therapy and hyperlipidemia on white matter integrity in CSVD patients.
objectiveTo investigate the independent effects of hyperlipidemia and statin therapy on white matter damage in CSVD by examining their relationship with serum myelin basic protein (MBP) levels, Fazekas scores, and hippocampal structure.
methodsThis study recruited 141 participants from Fuyang City, China, with 71 CSVD patients and 70 NCSVD controls. Participants underwent multimodal cranial MRI, cognitive assessments, and blood tests. Statistical analyses explored the relationships between MBP levels, Fazekas scores, hippocampal fimbria volume, and statin therapy.
resultsStatin therapy was significantly associated with lower Fazekas scores (p = 0.018), decreased MBP levels (p = 0.006), and higher hippocampal fimbria volumes (p = 0.009 for left fimbria, p = 0.010 for right fimbria) only in the CSVD group. Hyperlipidemia and blood lipid levels showed no statistically significant associations with Fazekas scores, MBP levels, or hippocampal fimbria volumes in either group.
conclusionThis study demonstrates that statin therapy is independently associated with reduced white matter damage in CSVD, irrespective of peripheral lipid levels. This protective effect is specific to CSVD patients, possibly related to statin therapy improving dysregulated central nervous system lipid metabolism following blood-brain barrier dysfunction. These findings provide new insights into CSVD pathophysiology and highlight the potential of statins as a therapeutic strategy for white matter protection in CSVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.